Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy

Page 5 of 10

6. Axsome Therapeutics Inc. (NASDAQ:AXSM)

Market Capitalization: $9.29 billion

Number of Hedge Fund Holders: 42

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to buy according to top investors. On January 20, H.C. Wainwright boosted its price target for Axsome Therapeutics Inc. (NASDAQ:AXSM) to $260 from $200 and kept a Buy rating on the biopharma’s shares. The spike comes after Axsome Therapeutics Inc. (NASDAQ:AXSM) announced interim unaudited financial results for the fourth quarter of 2025, with total product revenue projected to be about $196 million.

Axsome Therapeutics Inc. (NASDAQ:AXSM) expects overall product revenue to be around $638.5 million in fiscal year 2025, an improvement of 66% over fiscal year 2024 and higher than H.C. Wainwright’s prediction of $628.3 million. The company’s primary product, AUVELITY, is projected to bring in net sales of about $155.1 million in Q4 and $507.1 million in the full year 2025, far exceeding the firm’s annual sales estimate of $397 million.

The company’s other products also performed well, with SUNOSI projected to clock in $36.7 million in Q4 revenue and $124.8 million for the year.

Axsome Therapeutics Inc. (NASDAQ:AXSM) is a biopharmaceutical company that develops and delivers novel therapies for the management of central nervous system/CNS disorders in the US.

Page 5 of 10